Our previous work demonstrated the efficacy of an antisense oligonucleotide (ASO) targeting a nonsense-mediated decay (NMD) exon in SCN1A to overcome Nav1.1 haploinsufficiency in a mouse model of DS (54). The gene discussed is SCN1A; the disease is Dravet syndrome.